Stay updated on Doxorubicin Plus Checkpoint Blockade in Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Doxorubicin Plus Checkpoint Blockade in Sarcomas Clinical Trial page.

Latest updates to the Doxorubicin Plus Checkpoint Blockade in Sarcomas Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedRevision: v3.6.6 was added to the study record history, replacing the previous Revision: v3.6.5. This update reflects a minor platform revision documented in the history.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe study history shows a new revision tag, v3.6.5, replacing v3.6.4, indicating a newer version of the study record has been published. This is an internal update and does not change the visible study details.SummaryDifference0.1%

- Check43 days agoChange DetectedAdds Revision: v3.6.4 to the study history and removes Revision: v3.6.3 from the history. This reflects a minor update to the record's version metadata.SummaryDifference0.1%

- Check64 days agoChange DetectedRecord History now lists a new revision entry, v3.6.3, replacing v3.6.2. This represents an update to the page's revision metadata shown in the study record history.SummaryDifference0.1%

- Check71 days agoChange DetectedThe page's revision label was updated from v3.6.0 to v3.6.2, reflecting a minor platform update shown in the record history.SummaryDifference0.1%

- Check85 days agoChange DetectedRecruitment status updated to 'No longer looking for participants', reflecting a major change in participant availability. The record history adds a new revision note 'v3.6.0' and removes the prior 'v3.5.5' entry, updating the version history.SummaryDifference0.3%

Stay in the know with updates to Doxorubicin Plus Checkpoint Blockade in Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Doxorubicin Plus Checkpoint Blockade in Sarcomas Clinical Trial page.